The list of compensated drugs will be extended and will be by 50% longer on 2015. This will lead to lower costs for patients, especially elderly persons and those who suffer from chronic diseases. This is one of the measures of the plan of actions approved by order of the Government, which is aimed at stabilizing the medicines market, IPN reports.
After a working meeting that centered on the situation on the pharmaceutical market and the provision of the population with drugs, Prime Minister Pavel Filip said the given plan of actions is aimed at ensuring high-quality and accessible drugs and at making the market more or less liberalized. “Emphasis will be placed on the price not of a shot, but of the treatment in general. I requested all the authorities covered by this plan of action to monitor attentively its implementation,” stated the Premier.
The plan envisions the simplification of the access of drugs from highly developed countries, such as the EU member states, the U.S. and Japan, to the Moldovan market as this means diversity and quality. “We aim to extend the chains of drugstores in village by simplifying all the registration procedures and the access to the market. We will also exclude the raw materials used to make drugs from the list of goods on which customs duties are paid,” said Pavel Filip.
He noted that transparency will be ensured in the process of purchasing drugs, the purchasing terms will be reduced and new models of procurement will be tested. A number of medicines that do not necessitate medical prescriptions will be removed from the national catalogues of prices.
According to the Premier, the problem of drugs is a complex one and requires an as complex approach. “Particular renowned foreign producers started to disappear from the home market. A number of drugs began to disappear and the people had to ask relatives or friends to buy medicines from Romania or Ukraine. We thus made effort to eliminate all these constraints and barriers. We tried to provide compensation mechanisms, but want to also allow those that supply drugs to make a normal profit, not yet over-profit,” said Pavel Filip.
